These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 21537036)
1. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036 [TBL] [Abstract][Full Text] [Related]
2. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. Anderson C; Nichols HB; House M; Sandler DP Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499 [TBL] [Abstract][Full Text] [Related]
3. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826 [TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236 [TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250 [TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Levine M; Moutquin JM; Walton R; Feightner J; CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210 [TBL] [Abstract][Full Text] [Related]
7. Exemestane for primary prevention of breast cancer in postmenopausal women. Zhang Y; Simondsen K; Kolesar JM Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103 [TBL] [Abstract][Full Text] [Related]
8. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer prevention trials. Rhodes DJ; Hartmann LC; Perez EA Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893 [TBL] [Abstract][Full Text] [Related]
10. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727 [TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG; J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307 [TBL] [Abstract][Full Text] [Related]
12. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Vogel VG Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706 [TBL] [Abstract][Full Text] [Related]
13. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer in postmenopausal women. Geller BA; Vogel VG Breast Dis; 2005-2006; 24():79-92. PubMed ID: 16917141 [TBL] [Abstract][Full Text] [Related]
15. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271 [TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Vogel VG Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712 [TBL] [Abstract][Full Text] [Related]
17. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort. Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889 [TBL] [Abstract][Full Text] [Related]
18. Current concepts in breast cancer chemoprevention. Chlebowski RT Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of breast cancer. Thomsen A; Kolesar JM Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189 [TBL] [Abstract][Full Text] [Related]
20. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Waters EA; McNeel TS; Stevens WM; Freedman AN Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]